Study:
A Phase II Pilot Trial of CHOP Followed by Iodine-131-Labeled Monoclonal Anti-B1 Antibody for Treatment of Newly Diagnosed Follicular Non-Hodgkin`s Lymphomas
Rationale:
Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Combining more than one drug may kill more cancer cells.
Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing
substances to them without harming normal cells.
Purpose:
Phase II trial to study the effectiveness of combination chemotherapy followed by
monoclonal antibody therapy in treating patients who have newly diagnosed follicular
non-Hodgkin`s lymphoma.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Lymphoma |
Drug: CHOP regimen
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: prednisone
Drug: vincristine sulfate
Radiation: tositumomab and iodine I 131 tositumomab |
Phase 2 |
Verified by
Southwest Oncology Group
January, 2013
Sponsored by: Southwest Oncology Group
Information provided by: Southwest Oncology Group
ClinicalTrials.gov identifier: NCT00003784
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States
Oliver W. Press, MD, PhD., Study Chair